Literature DB >> 10671762

Efficacy of amikacin, ofloxacin, pefloxacin, ciprofloxacin, enoxacin and fleroxacin in experimental left-sided Pseudomonas aeruginosa endocarditis.

J A Papadakis1, G Samonis, S Maraki, J Boutsikakis, V Petrocheilou, G Saroglou.   

Abstract

The efficacies of amikacin, ofloxacin, pefloxacin, ciprofloxacin, enoxacin and fleroxacin, each as monotherapy, were evaluated in a rabbit model of induced left-sided Pseudomonas aeruginosa endocarditis. Therapy started 48 h after infection and lasted 5 days. All agents were given intramuscularly; amikacin at 7 mg/kg/12 h, and each quinolone at 35 mg/kg/12 h. All animals survived except for 1 of the group that received amikacin, and 2 of the untreated control group. No sterile vegetations were found in the untreated group and the group of fleroxacin, while 3 animals from the amikacin, ofloxacin, and enoxacin groups, and 2 from the ciprofloxacin and pefloxacin groups had sterile vegetations. All agents used significantly reduced the number of CFU per gram of vegetation versus untreated controls. Enoxacin and ciprofloxacin were equipotent and more effective than pefloxacin, ofloxacin and amikacin. Fleroxacin had a weaker activity. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10671762     DOI: 10.1159/000007265

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  2 in total

1.  Diffusion of ofloxacin in the endocarditis vegetation assessed with synchrotron radiation UV fluorescence microspectroscopy.

Authors:  Eric Batard; Fréderic Jamme; Sandrine Villette; Cédric Jacqueline; Marie-France de la Cochetière; Jocelyne Caillon; Matthieu Réfrégiers
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

2.  Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.

Authors:  Frank Oechslin; Philippe Piccardi; Stefano Mancini; Jérôme Gabard; Philippe Moreillon; José M Entenza; Gregory Resch; Yok-Ai Que
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.